Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 2/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5549561 | 0.85 | SMN1; SMN2 (0.65) | MAPTSMN1; SMN2TP53THRBRXFP1 | |
| SCHEMBL4004290 | 0.75 | RAB9A (0.62) | MAPTSMN1; SMN2TP53NPC1RAB9A | |
| SCHEMBL7932793 | 0.75 | RAB9A (0.62) | MAPTSMN1; SMN2TP53NPC1RAB9A | |
| SCHEMBL3771751 | 0.74 | RAB9A (0.74) | MAPTSMN1; SMN2TP53NPC1RAB9A | |
| SCHEMBL5549567 | 0.74 | MAPT (0.70) | MAPTSMN1; SMN2THRBRXFP1NPC1 | |
| SCHEMBL5544376 | 0.74 | KMT2A (0.56) | MAPTSMN1; SMN2ADORA3ADORA2AADORA1 | |
| SCHEMBL4867130 | 0.73 | RAB9A (0.59) | MAPTSMN1; SMN2TP53NPC1RAB9A | |
| SCHEMBL14026235 | 0.72 | NPC1 (0.49) | MAPTSMN1; SMN2TP53NPC1RAB9A | |
| SCHEMBL2175321 | 0.72 | RAB9A (0.69) | MAPTSMN1; SMN2TP53NPC1RAB9A | |
| SCHEMBL19662758 | 0.70 | RAB9A (0.75) | MAPTSMN1; SMN2TP53NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1785134-A2 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | ALTEON, INC. (US) | 2007-05-16 | — | — | EP | disclosed |
| US-20060014781-A1 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | SYNVISTA THERAPEUTICS, INC. | 2006-01-19 | — | — | US | disclosed |
| US-6960605-B2 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | ALTEON, INC. (US) | 2005-11-01 | — | — | US | disclosed |
| EP-1248615-A4 | THIAZOLE, IMIDAZOLE AND OXAZOLE COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | ALTEON INC (US) | 2004-08-04 | — | — | EP | disclosed |
| EP-1248615-A1 | THIAZOLE, IMIDAZOLE AND OXAZOLE COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | Alteon, Inc. (US) | 2002-10-16 | — | — | EP | disclosed |
| US-20020022622-A1 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | SYNVISTA THERAPEUTICS, INC. | 2002-02-21 | — | — | US | disclosed |
| WO-2001052847-A1 | THIAZOLE, IMIDAZOLE AND OXAZOLE COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | ALTEON, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022622-A1 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | ABAT, NDUFAB1, HSPE1 | MAPT 314/4885SMN1; SMN2 381/4885TP53 650/4885 |
| US-20060014781-A1 | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | ABAT, HSPE1, TXN2 | MAPT 136/4885SMN1; SMN2 459/4885TP53 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.